Background: Pharmacy practice includes the handling of human and animal medication. Amongst veterinary pharmaceutical treatments, the management of Canine Atopic Dermatitis (CAD), a chronic skin condition affecting 10%–15% of the canine population, is complex and demanding. Medication regimens are tailored to each animal and their owner or caregiver. The purpose of this study was to assess the impact of a mobile health (m-health) application (Petable®) to support the medication adherence in CAD treatment and clinical improvement. Methods: A total of 30 atopic dogs under treatment for CAD and their caregivers were enrolled. Both the dogs’ and owners’ background data were recorded as well as clinical and medication adherence information. This was accomplished by direct observation, clinical files consultation, mobile application, and medication adherence (Medida de Adesão aos Tratamentos—MAT questionnaire) feedback. Results: The overall non-adherence of the sample was 12.6% according to the mobile application, while 60% of caregivers self-scored as adherent according to the MAT. The only significant and positive correlation was between overall adherence and the caregiver’s education. The average degree of pruritus decreased over time and during treatment, independently to the level of m-health app usage. Conclusions: The adherence to chronic treatments may be improved through m-health apps, although further studies are needed to gauge their actual usefulness in supplementing known adherence determinants.
Canine atopic dermatitis (cAD) is a common and distressing skin condition in dogs, affecting up to 30% of the canine population. It not only impacts their quality of life but also that of their owners. Like human atopic dermatitis (hAD), cAD has a complex pathogenesis, including genetic and environmental factors. Current treatments focus on managing clinical signs, but they can be costly and have limitations. This article emphasizes the importance of preventing cAD from developing in the first place. Understanding the role of the skin’s protective barrier is crucial, as its dysfunction plays a vital role in both hAD and cAD. hAD prevention studies have shown promising results in enhancing the skin barrier, but more research is needed to support more robust conclusions. While hAD primary prevention is currently a focal point of intensive investigation in human medicine, research on cAD primary prevention remains under-researched and almost non-existent. Pioneering effective prevention strategies for cAD holds immense potential to enhance the quality of life for both dogs and their owners. Additionally, it bears the promise of a translational impact on human research. Hence, further exploration of this crucial topic is not only relevant but also timely and imperative, warranting support and encouragement.
Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) and profoundly impacts the patients’ quality of life. The increasing number of new drugs in development for atopic dermatitis indicates both the need and potential for precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known for its potential anti-inflammatory and antipruritic properties, shows promise in hAD and cAD management, prompting the exploration of cannabinoids (CBs) and CBD as therapeutic tools. In fact, encouraging results on the benefits of using CBD in cAD have been published, along with safety evaluations that reveal that CBD is generally well tolerated in dogs. However, limited placebo-controlled trials and dosage variations in dogs pose barriers that hinder definitive conclusions. Challenges in product stability, inconsistent formulations, and legal ambiguities highlight the need for standardised CBD-based products for both research and commercial uses. The complex legal landscape further complicates accessibility and regulation. Despite these challenges, CBD is emerging as a potential avenue for cAD management, urging further high-quality research, standardised formulations, and legal clarity. This brief review provides valuable insights into the therapeutic potential of CBs and CBD in cAD, compared to hAD, emphasising the importance of rigorous research and unambiguous regulation for successful integration into veterinary dermatology.